INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $234,000 | -34.3% | 16,800 | -23.1% | 0.00% | 0.0% |
| Q4 2021 | $356,000 | -46.3% | 21,855 | -51.0% | 0.00% | -50.0% |
| Q3 2021 | $663,000 | -44.8% | 44,623 | -25.8% | 0.00% | -60.0% |
| Q2 2021 | $1,200,000 | +81.3% | 60,100 | +109.4% | 0.01% | +66.7% |
| Q1 2021 | $662,000 | +138.1% | 28,704 | +155.3% | 0.00% | +200.0% |
| Q4 2020 | $278,000 | -77.8% | 11,244 | -43.5% | 0.00% | -88.9% |
| Q1 2020 | $1,252,000 | +78.9% | 19,898 | +252.9% | 0.01% | +80.0% |
| Q4 2019 | $700,000 | -10.6% | 5,639 | -52.2% | 0.01% | -28.6% |
| Q3 2019 | $783,000 | +66.6% | 11,800 | +180.8% | 0.01% | +133.3% |
| Q1 2019 | $470,000 | -2.1% | 4,202 | +10.6% | 0.00% | 0.0% |
| Q3 2018 | $480,000 | – | 3,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $39,083,000 | 9.04% |
| Senvest Management, LLC | 1,152,032 | $70,873,000 | 5.40% |
| Melqart Asset Management (UK) Ltd | 298,200 | $18,345,000 | 2.20% |
| Elk Creek Partners, LLC | 348,454 | $21,437,000 | 1.25% |
| ALTRINSIC GLOBAL ADVISORS LLC | 375,223 | $23,084,000 | 0.93% |
| BB BIOTECH AG | 545,719 | $33,573,000 | 0.93% |
| Virtus ETF Advisers LLC | 14,681 | $903,000 | 0.78% |
| Opus Point Partners Management, LLC | 4,496 | $277,000 | 0.54% |
| Spark Investment Management LLC | 136,500 | $8,397,000 | 0.54% |
| Regal Investment Advisors LLC | 29,511 | $1,816,000 | 0.40% |